Inactive FSH in Galactosemia

NCT ID: NCT00619333

Last Updated: 2010-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate whether inactive FSH plays a role in the development of Premature Ovarian Failure in women with Classic Galactosemia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Galactosemia Premature Ovarian Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type OTHER

follitropin and lutropin

Intervention Type DRUG

follitropin and lutropin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

follitropin and lutropin

follitropin and lutropin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of galactosemia through GALT-activity analysis and/or mutation analysis
* Premature Ovarian Failure with FSH \> 30 U/l

Exclusion Criteria

* Gynecological cancers and/or unexplained vaginal bleeding
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Dutch Galactosemia Society

OTHER

Sponsor Role collaborator

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Academic Hospital Maastricht

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Estela Rubio-Gozalbo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University Hospital

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MEC 06-2-073

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PREPL in Health and Disease
NCT02263781 ACTIVE_NOT_RECRUITING NA